Photys Therapeutics utilizes a proprietary platform of bifunctional small molecules to precisely control protein post-translational modifications, enhancing the phosphorylation of target proteins. This technology aims to restore protein function and amplify disease-fighting mechanisms, addressing the challenges of dysfunctional protein signaling in various diseases.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are characterized by dysfunctional protein signaling due to impaired post-translational modifications. Current therapeutic approaches often fail to restore normal protein function and leverage the body's natural disease-fighting mechanisms.
Solution
Photys Therapeutics develops bifunctional small molecules that precisely control protein post-translational modifications, specifically enhancing protein phosphorylation. Their Phosphorylation-Inducing Chimeric Small Molecules (PHICS) platform induces proximity between specific kinases and target proteins, modulating key protein functions by enabling precise phosphorylation at native or non-native sites. This approach aims to restore protein function, repair signaling pathways, and amplify endogenous disease-fighting mechanisms. By going beyond protein degradation, Photys' technology offers a novel way to address diseases driven by dysfunctional protein signaling.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing therapies for diseases characterized by dysfunctional protein signaling.
Features
- Proprietary platform of bifunctional small molecules for targeted protein phosphorylation
- PHICS (Phosphorylation-Inducing Chimeric Small Molecules) technology to enhance kinase-target protein pairing
- Ability to induce phosphorylation at both native and non-native sites on target proteins
- Modulation of key protein functions through precise control of phosphorylation